Baker Ellis Asset Management LLC Cardiff Oncology, Inc. Transaction History
Baker Ellis Asset Management LLC
- $695 Million
- Q3 2024
A detailed history of Baker Ellis Asset Management LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Baker Ellis Asset Management LLC holds 20,000 shares of CRDF stock, worth $55,800. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,000Holding current value
$55,800% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
100Shares Held
12.8MCall Options Held
823KPut Options Held
78K-
Black Rock Inc. New York, NY2.63MShares$7.33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$5.96 Million0.0% of portfolio
-
Assenagon Asset Management S.A.1.22MShares$3.39 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA911KShares$2.54 Million0.0% of portfolio
-
State Street Corp Boston, MA805KShares$2.25 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $121M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...